J 2020

Identification of Novel Carbonic Anhydrase IX Inhibitors Using High-Throughput Screening of Pooled Compound Libraries by DNA-Linked Inhibitor Antibody Assay (DIANA)

TYKVART, Jan, Václav NAVRÁTIL, Michael KUGLER, Pavel ŠÁCHA, Jiří SCHIMER et. al.

Základní údaje

Originální název

Identification of Novel Carbonic Anhydrase IX Inhibitors Using High-Throughput Screening of Pooled Compound Libraries by DNA-Linked Inhibitor Antibody Assay (DIANA)

Autoři

TYKVART, Jan (203 Česká republika, garant), Václav NAVRÁTIL (203 Česká republika), Michael KUGLER (203 Česká republika), Pavel ŠÁCHA (203 Česká republika), Jiří SCHIMER (203 Česká republika), Anna HLAVÁČKOVÁ (203 Česká republika), Lukáš TENORA (203 Česká republika, domácí), Jitka ZEMANOVÁ, Jitka DEJMEK, Vlastimil KRÁL, Milan POTÁČEK (203 Česká republika, domácí), Pavel MAJER, Ullrich JAHN, Jiří BRYNDA, Pavlína ŘEZÁČOVÁ a Jan KONVALINKA

Vydání

SLAS Discovery, SAGE Publications Inc, 2020, 2472-5552

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.918

Kód RIV

RIV/00216224:14310/20:00116956

Organizační jednotka

Přírodovědecká fakulta

UT WoS

000535984500001

Klíčová slova anglicky

high-throughput screening; carbonic anhydrase IX; drug discovery; DNA-linked inhibitor antibody assay

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 27. 11. 2020 09:29, Mgr. Marie Šípková, DiS.

Anotace

V originále

The DNA-linked inhibitor antibody assay (DIANA) has been recently validated for ultrasensitive enzyme detection and for quantitative evaluation of enzyme inhibitor potency. Here we present its adaptation for high-throughput screening of human carbonic anhydrase IX (CAIX), a promising drug and diagnostic target. We tested DIANA's performance by screening a unique compound collection of 2816 compounds consisting of lead-like small molecules synthesized at the Institute of Organic Chemistry and Biochemistry (IOCB) Prague (“IOCB library”). Additionally, to test the robustness of the assay and its potential for upscaling, we screened a pooled version of the IOCB library. The results from the pooled screening were in agreement with the initial nonpooled screen with no lost hits and no false positives, which shows DIANA’s potential to screen more than 100,000 compounds per day.All DIANA screens showed a high signal-to-noise ratio with a Z factor of >0.89. The DIANA screen identified 13 compounds with Ki values equal to or better than 10 uM. All retested hits were active also in an orthogonal enzymatic assay showing zero false positives. However, further biophysical validation of identified hits revealed that the inhibition activity of several hits was caused by a single highly potent CAIX inhibitor, being present as a minor impurity. This finding eventually led us to the identification of three novel CAIX inhibitors from the screen. We confirmed the validity of these compounds by elucidating their mode of binding into the CAIX active site by x-ray crystallography.